- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | US FDA accepts regulatory submission for Selumetinib | ||
| Fr | EpicentRx closes $35m series D financing to support development of small molecule immunotherapy and oncolytic viral platform | ||
| Fr | Shionogi gets FDA approval for cUTI drug Fetroja | ||
| Do | GSK's mepolizumab succeeds in phase 3 trial in hypereosinophilic syndrome | ||
| Do | Finch Therapeutics, Takeda expand collaboration to develop microbiome therapeutics | ||
| Do | RDD Pharma signs LOI to acquire Naia Rare Diseases | ||
| Do | Merck to acquire Calporta Therapeutics for $576m | ||
| Mi | Lupin to sell its stake in Kyowa to Unison for $526m | ||
| Mi | Mylan, Pfizer announce Viatris as new company name | ||
| Mi | X4 Pharmaceuticals receives breakthrough therapy designation from FDA for Mavorixafor to treat WHIM Syndrome | ||
| Mi | Boehringer, Eli Lilly begin sixth phase III study for Jardiance in heart failure | ||
| Di | Roche's risdiplam meets primary endpoint in phase 3 SMA trial | ||
| Di | NEC and VAXIMM announce collaboration to advance personalized neoantigen cancer vaccines | ||
| Di | Novartis' Sandoz to buy Aspen's Japanese business in $441m deal | ||
| Di | ATAI Life Sciences and Cyclica launch joint venture to revolutionise drug development for mental health disorders | ||
| Mo | Stone Capital Partners Biosyngen to setup $50m biopharmaceutical investment fund in Singapore | ||
| Mo | AbbVie submits sNDA to FDA for IMBRUVICA, Rituximab combo for CLL | ||
| Mo | FDA approves Reblozyl for treatment of anaemia in beta thalassemia | ||
| 08.11. | Roxadustat significantly increased hemoglobin levels for chronic kidney disease patients with anemia in phase III OLYMPUS and ROCKIES trials | ||
| 08.11. | Johnson & Johnson seeks EMA approval for Ebola vaccine regimen | ||
| 08.11. | Takeda's dengue vaccine candidate demonstrates protection in children ages four to 16 years | ||
| 07.11. | Samsung Bioepis enters into commercialisation agreement for next-generation biosimilar candidates | ||
| 07.11. | Axcella achieves initial milestones with its hematology product candidate AXA4010 | ||
| 07.11. | Regeneron, Vyriad sign deal to develop oncolytic virus-based treatments | ||
| 06.11. | Cyclica collaborates with Enamine to use REAL technology in its ligand design platform for AI-augmented drug design |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
